Showing 2664 results
- Key Release /Basel, February 1, 2018 - Novartis AG (NYSE: NVS) today announced the completion of the subsequent offering period of the tender offer by its subsidiary, Novartis Groupe France S.A., to purchase all…
- Media Release /Glatopa® 40 mg/mL is a fully substitutable, AP-rated generic version of Copaxone®* (glatiramer acetate injection) 40 mg/mL Glatopa 40 mg/mL, along with Glatopa® 20 mg/mL, which was launched…
- Media Release /Majority of patients with scalp psoriasis on Cosentyx® (secukinumab) achieved clear skin (PSSI 90) at Weeks 12 and 24 and improved quality of life[1] Scalp psoriasis affects 60 million…
- Media Release /Novartis receives funding from Bill & Melinda Gates Foundation for further development of Novartis drug candidate KDU731 for the treatment of cryptosporidiosis Cryptosporidiosis is the…
- Media Release /Two thirds of patients on Cosentyx® (secukinumab) reported no impact of skin disease on their quality of life over 5 years, SCULPTURE study shows[1] Findings show absolute PASI <=1/…
- Media Release /Ultibro® Breezhaler® provided significant improvements in cardiac and lung function in COPD patients with lung hyperinflation, compared to placebo CLAIM is the first study to…
- Media Release /Novartis and Pear Therapeutics to collaborate on prescription software applications aimed to treat patients with schizophrenia and multiple sclerosis Collaboration combines Novartis'…
- Media Release /Aktionäre genehmigen für 2017 die 21. Dividendenerhöhung in Folge auf CHF 2,80 pro Aktie (+2%) - dies entspricht einer Rendite von 3,6% und einer Ausschüttungsquote von rund 67% des Free Cashflow…
- Media Release /Les actionnaires approuvent la 21e hausse consécutive du dividende, à CHF 2,80 (+2 %) par action au titre de l'exercice 2017, soit un rendement de 3,6 % et une distribution du free cash-…
- Media Release /Shareholders approve 21st consecutive dividend increase to CHF 2.80 (+2%) per share for 2017; representing a 3.6% yield and approximately 67% payout of free cash flow Dr. Joerg Reinhardt…